Leptin and TNF-Alpha Levels in Patients with Chronic Obstructive Pulmonary Disease and Their Relationship to Nutritional ParametersÇalıkoglu M.a · Şahin G.b · Unlu A.c · Ozturk C.d · Tamer L.c · Ercan B.c · Kanik A.e · Atik U.c
Departments of aChest Disease, bPhysical Medicine and Rehabilitation, cBiochemistry, dMicrobiology and eBiostatistics, Mersin, Turkey
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Leptin is a protein mainly secreted by adipocytes, and the major function of leptin was its role in body weight regulation. In humans, there was a strong correlation between leptin and nutritional parameters, such as body mass index (BMI) and fat mass (FM). Administration of recombinant leptin to ob/ob mice, which have a genetic defect in leptin production, reduces food intake, increases energy expenditure, and decreases body weight. It is suggested that increased levels of circulating leptin levels may contribute to anorexia and weight loss in pathologic conditions including chronic obstructive pulmonary disease (COPD). Recent studies have provided evidence for a link between leptin and proinflammatory cytokines such as TNF-α. Objective: This study aimed to detect serum leptin and TNF-α levels in COPD patients without weight loss during stable disease and acute exacerbation, and to investigate relationships between leptin, TNF-α and nutritional parameters at different stages of the disease. Material and Methods: 26 stable COPD patients, 16 COPD patients with acute exacerbation and 15 control subjects participated in this study. To eliminate the effects of sex differences, all patients and controls were male. BMI, percent ideal body weight, percent FM, sum of skinfold tickness and serum leptin and TNF-α levels were measured in all participants. Leptin and TNF-α levels were measured by ELISA. Results: Serum leptin and TNF-α levels were significantly higher in the patients experiencing exacerbation than in the stable patients and controls. Although leptin levels were lower and TNF-α levels were higher in the stable patient group than in the controls, these differences were not statistically different. Leptin levels were significantly correlated with the nutritional parameters in both control and stable groups. However, in patients with acute exacerbation, a correlation between leptin and nutritional parameters was not found. There was no significant relationship between TNF-α and nutritional parameters in the three groups. In addition, while there was no correlation between leptin and TNF-α levels in the stable and control groups, a significant positive correlation was observed in patients with exacerbation. Conclusion: In conclusion (1) elevated TNF-α levels may be related to increased inflammation in patients, (2) circulating TNF-α levels were associated with increased leptin levels and (3) although leptin and nutritional parameters were correlated in the stable COPD patients, the correlation was weaker compared to controls, and during an exacerbation it disappeared completely. Therefore, inappropriately increased levels of leptin and TNF-α noted during recurrent acute exacerbations in patients with COPD may lead to changes in nutritional parameters and body weight in the course of the disease.
© 2004 S. Karger AG, Basel
- Wauters M, Considine RV, Gaal GFV: Human leptin: From an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000;143:293–311.
- Tartaglia LA: The leptin receptor. J Biol Chem 1997;272:6093–6096.
- Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292–295.
- Lönnqvist F, Arner P, Nordfords L, Schalling M: Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1995;1:950–953.
- Hamilton BS, Paglia D, Kwan AY, Deitel M: Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995;1:953–956.
- Maffei M, Halaas J, Ravussin E, et al: Leptin levels in human and rodent: Measurement of plasma leptin and ob gene mRNA in obese and weight-reduced subjects. Nat Med 1995;1:1155–1161.
- Merabet E, Dagogo-Jack S, Coyne DW, et al: Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997;82:847–850.
- Grunfeld C, Zhao C, Fuller J, et al: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters: A role for leptin in the anorexia of infection. J Clin Invest 1996;97:2152–2157.
- De Vos P, Saladin R, Auwerx J, Staels B: Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 1995;270:15958–15961.
Barrazzone-Argiroffo C, Muzzin P, Donati YR, Kan CD, Aubert MI, Piguet PF: Hyperoxia increases leptin production: A mechanism mediated through endogenous elevation of corticosterone. Am J Physiol Lung Cell Mol Physiol 2001;281:L1150–L1156.
- Takabatake N, Nakamura H, Abe S, et al: Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1215–1219.
Creutzberg EC, Wouters EFM, Vanderhoven-Augustin IML, Dentener MA, Schols AMWJ: Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am Respir Crit Care Med 2000;162:1239–1245.
- Di Francia M, Barbier D, Mege JL, Orehek J: Tumor necrosis factor alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453–1455.
- de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM: Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996;153:633–637.
- Argiles JM, Soriano, Lopez J, Busquets S: Journey from cachexia to obesity by TNF. FASEB J 1997;11:743–775.
Balkwill F, Osborne R, Burke F, et al: Evidence for tumor necrosis factor cachectin production in cancer. Lancet 1987;ii:1229–1232.
- Norman D, Elborn JS, Cordon SM, et al: Plasma TNF-alpha in cystic fibrosis. Thorax 1991;46:91–95.
- Mueller R, Chanez P, Champell AM, Bousquet J, Heusser C, Bulloc GR: Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996;90:79–85.
- Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530–534.
American Thoracic Society: Standards for diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:77–120.
Metropolitan Life Insurance Company: New weight standards for men and women. Stat Bull Metrop Life Found 1983;64:1–4.
- Quanjer PH: Standardized lung function testing. Bull Eur Physiopathol Respir 1983;19:7–44.
Yuan Y, Wang Z, Liu C: Preliminary investigation of the effect of serum leptin on the nutritional state of COPD patients (in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2000;23:292–295.
- Schols AMWJ, Creutzberg EC, Buurman WA, Campfield LA, Saris WHM, Wouters EFM: Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1220–1226.
- Yamamoto C, Yoneda T, Yoshikawa M, et al: The relationship between a decrease in fat mass and serum levels of TNF-alpha in patients with chronic obstructive pulmonary disease (in Japanese). Nihon Kyobu Shikkan Gakkai Zasshi 1997;35:1191–1195.
Sarraf P, Frederich RC, Turner EM, et al: Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia. J Exp Med 1997;1:171–175.
- Zumbach MS, Boehme MWJ, Wahl P, Stremmel W, Zie R, Nawroth PP: Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab 1997;82:4080–4082.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.